By guest blogger Chanice Henry, Editor, Pharma IQ
Even though drug development for Alzheimer’s Disease has a steep failure rate, the lessons learned from failed trials are of great benefit to future research.
Alzheimer’s is the most common form of dementia – the irreversible loss of memory and other cognitive functions which eventually makes daily tasks unmanageable.
As the life expectancy of the world’s population grows, the Alzheimer’s is becoming more common. Estimates suggest that the number of affected US patients will climb from 5.3 million to almost 14 million by 2050.
In the fight against this disease many have dedicated their careers to revolutionise how the neurodegenerative disease is diagnosed and handled.
By IGHI guest blogger, Chris Bird, PG student in the Centre for Health Policy and Project Manager in the System Engagement Programme at the National Institute for Health and Care Excellence (NICE)
In today’s fast moving world, we need to constantly adapt to keep up. But what about those people in later life who might struggle to do so?
We live in a world where society is ageing. Falling mortality rates, particularly in the over 65-year age group coupled with low fertility rates in the younger population are leading to a society which is growing older[i].It is also true that conventional care delivery is often based around admittance to institutionalised hospital care which is both costly and can be inefficient as professionals, bound by silo working, fail to achieve either best value or best care for patients[ii].